Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
LIQ001 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Fluzone + 0.45 mg LIQ001 | EXPERIMENTAL | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (0.45mg) |
| Fluzone + 1.8 mg LIQ001 | EXPERIMENTAL | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) Administered with LIQ001 (1.8mg) |
| Fluzone | ACTIVE_COMPARATOR | Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) |
| Name | Type | Description |
|---|---|---|
| Fluzone® (2010/2011 Inactivated Trivalent Influenza Vaccine) | BIOLOGICAL | A single vaccination of Fluzone alone |
| LIQ001 (0.45mg) | BIOLOGICAL | A single vaccination of 0.45 mg LIQ001 |
| LIQ001 (1.8mg) | BIOLOGICAL | A single vaccination of 1.8 mg LIQ001 |
Inclusion Criteria: * Age 18 to 49 years (Cohort 1) and age 65 or above (Cohort 2) * For subjects 18 to 49 years of age: in good health as determined by medical history, physical examination, and the clinical judgment of the Principal Investigator (PI) * For subjects 65 years of age and older: in s...
Top 8 of 11 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GSK plc Sponsored ADR | GSK | 3 | PHASE3 | mRNA Seasonal Flu vaccine, Flu/COVID-19 mRNA combination vaccine |
| Sinovac Biotech Ltd. | SVA | 1 | PHASE3 | Quadrivalent influenza vaccine (split virion), inactivated |
| Moderna, Inc. | MRNA | 2 | PHASE3 | mRNA-1018-H5, mRNA-1010, Fluarix Trivalent |
| Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | CDTX | 1 | PHASE3 | CD388 |
| Traws Pharma, Inc. | TRAW | 2 | PHASE2 | TRX-100 |
| Sanofi SA Sponsored ADR | SNY | 4 | PHASE1 | H5N8 pandemic influenza vaccine (adjuvanted) |
| Hoffmann-La Roche | RHHBY | 2 | PHASE3 | Baloxavir Marboxil |
| AstraZeneca PLC | AZN | 1 | PHASE1 | AZD4117, AZD5315 |
LIQ001 is an investigational monoclonal antibody developed by Liquidia Corporation (ticker: LQDA) for influenza. It has been studied as a component of a seasonal influenza vaccine in a Phase 1 clinical trial. LIQ001 is also known as LIQ001 (0.45mg).
LIQ001 is being developed for influenza, a contagious respiratory illness caused by influenza viruses. It has been evaluated in a Phase 1 trial as part of a seasonal influenza vaccine. The goal is to prevent influenza infection.
LIQ001 is developed by Liquidia Corporation, a biopharmaceutical company traded on the Nasdaq under the ticker symbol LQDA. Liquidia is responsible for the research and clinical development of LIQ001.
LIQ001 is in Phase 1 clinical development. It has completed one Phase 1 trial evaluating its safety and tolerability as part of a seasonal influenza vaccine. LIQ001 is investigational and has not been approved by the FDA.
LIQ001 has been studied in one completed Phase 1 clinical trial, NCT01224262, titled 'A Study Evaluating the Safety and Tolerability of a Seasonal Influenza Vaccine Containing LIQ001.' The trial enrolled 152 healthy adult volunteers in the United States and was randomized, double-blind, and active-controlled.